Citius Pharmaceuticals, Inc.
CTXR
$0.58
-$0.02-3.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 85.40% | 72.36% | 0.56% | -2.39% | 5.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.72% | 43.67% | -4.26% | -8.26% | 0.17% |
| Operating Income | -39.45% | -30.62% | 13.50% | 8.26% | -0.17% |
| Income Before Tax | -40.94% | -28.77% | 4.99% | 0.43% | -9.07% |
| Income Tax Expenses | -79.72% | -31.23% | 51.80% | 83.47% | 62.60% |
| Earnings from Continuing Operations | -38.25% | -27.64% | 4.01% | -0.80% | -9.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 557.41% | 563.09% | 270.81% | 703.62% | -- |
| Net Income | -14.92% | -9.88% | 9.55% | 4.36% | -5.15% |
| EBIT | -39.45% | -30.62% | 13.50% | 8.26% | -0.17% |
| EBITDA | -12.33% | -27.95% | 14.84% | 8.26% | -0.17% |
| EPS Basic | 57.06% | 54.79% | 49.77% | 35.54% | 18.67% |
| Normalized Basic EPS | 60.95% | 56.24% | 54.31% | 40.73% | 24.96% |
| EPS Diluted | 57.06% | 54.79% | 49.77% | 35.54% | 19.27% |
| Normalized Diluted EPS | 60.95% | 56.24% | 54.31% | 40.73% | 24.96% |
| Average Basic Shares Outstanding | 154.24% | 138.18% | 107.83% | 64.55% | 31.81% |
| Average Diluted Shares Outstanding | 154.24% | 138.18% | 107.83% | 64.55% | 31.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |